Login to Your Account



Amarin's Big Market Catch?

Fish Oil Drug Cuts Triglycerides in Second Phase III; NDA in 3Q

By Jennifer Boggs


Tuesday, April 19, 2011
Amarin Corp. plc's purified EPA omega-3 fatty acid compound AMR101 bested investor expectations in a second Phase III study, sending the Dublin, Ireland-based firm's shares soaring 95 percent Monday and potentially catapulted the drug into a multi-billion-market opportunity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription